NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
What's Going On With Esperion Therapeutics Stock On Tuesday? - Esperion Therapeutics (NASDAQ:ESPR) benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
The FDA has expanded the approval of Nexletol and Nexlizet to prevent myocardial infarction and coronary revascularization in both primary and secondary prevention patients.